Adopted opinions and previous consultations on applications for authorisation

This page provides further information on the applications for authorisation or review reports, which have undergone consultation. The applications for authorisation are in the opinion development phase until the final opinions of the Committees for Risk Assessment and Socio-economic Analysis have been adopted and sent to the European Commission. Its decision-making process can be followed through the comitology register, where further information is published about the REACH Committee's past and upcoming meetings.

On 1 February 2020, the United Kingdom (UK) withdrew from the EU. The transition period provided by the withdrawal agreement ended on 31 December 2020. As of 1 January 2021, an application for an authorisation submitted by a person established in the UK (except Northern Ireland) is no longer valid in the EU, unless that application has been transferred to a legal entity established in the EU or Northern Ireland before the end of the transition period. Therefore, authorisation applications and decisions in so far as these concern persons established in the UK (except Northern Ireland) are no longer considered valid.

ID	Application type	Name	EC Number	CAS Number	Applicant(s)	Use name	Status
0360-01	Initial	2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate	239-622-4	15571-58-1	Galata Chemicals GmbH; REAGENS SPA	Formulation of liquid mixtures containing DOTE	Opinion development	Details
0360-03	Initial	2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate	239-622-4	15571-58-1	Galata Chemicals GmbH; REAGENS SPA; PMC Vlissingen Netherlands B.V.	Industrial manufacture of PVC articles through extrusion, injection, calendering and coating using mixtures containing DOTE as stabilizer	Opinion development	Details
0349-01	Review report	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	bioMérieux SA	Industrial use of 4-tert-OPnEO for its non-ionic detergent properties, used for the extraction of biological material which is further formulated and coated on articles intended for clinical and industrial in vitro testing applications	Opinion development	Details
0350-02	Review report	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	PPG Europe B.V. in its legal capacity as Only Representative of PRC DeSoto International Inc.; PPG Europe B.V. in its legal capacity as Only Representative of PPG Industries (UK) Ltd.	Mixing, by Airbus, and their associated supply chains, including the Applicant, of base polysulfide sealant components with OPE-containing hardener, resulting in mixtures containing < 0.1% w/w of OPE for Aerospace and Defence uses that are exempt from authorisation under REACH Art. 56(6)(a)	Opinion development	Details
0350-01	Review report	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	PPG Europe B.V. in its legal capacity as Only Representative of PRC DeSoto International Inc.; PPG Europe B.V. in its legal capacity as Only Representative of PPG Industries (UK) Ltd.	Repackaging hardener formulations containing OPE as a surfactant in a concentration above 0.1%, to be used within two-part polysulphide sealants by Airbus and their associated supply chains	Opinion development	Details
0348-02	Review report	4-Nonylphenol, branched and linear, ethoxylated	-	-	Chemetall GmbH	Mixing, by Aerospace Companies and their associated supply chains, including the Applicant, of base polysulfide sealant components with NPE-containing hardener, resulting in mixtures containing < 0.1% w/w of NPE for Aerospace uses that are exempt from authorisation under REACH Art. 56(6)(a).	Opinion development	Details
0348-01	Review report	4-Nonylphenol, branched and linear, ethoxylated	-	-	Chemetall GmbH	The formulation of a hardener component containing NPE within Aerospace two-part polysulfide sealants.	Opinion development	Details
0358-01	Review report	Arsenic acid	231-901-9	7778-39-4	CIRCUIT FOIL LUXEMBOURG SARL	Industrial use of arsenic acid for the treatment of copper foil used in the manufacture of printed circuit board.	Opinion development	Details
0352-01	Initial	Bis(2-ethylhexyl) phthalate	204-211-0	117-81-7	Baxter SA; Baxter Healthcare SA; Gambro Dasco SpA; Baxter (Malta) Trading Co Ltd; Colorite Europe Ltd.	Formulation of DEHP mixtures for application in immediate packaging of medicines and medical devices	Opinion development	Details
0352-02	Initial	Bis(2-ethylhexyl) phthalate	204-211-0	117-81-7	Baxter SA; Baxter Healthcare SA; Gambro Dasco SpA; Baxter (Malta) Trading Co Ltd	Use of DEHP-containing plastics for immediate packaging of medicinal products	Opinion development	Details

Showing 131 - 140 of 567 results.

Export in: